Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Fukushima Medical University Human Genome Center, Institute of Medical Science, University of Tokyo |
---|---|
Information provided by: | Fukushima Medical University |
ClinicalTrials.gov Identifier: | NCT00655785 |
The purpose of this study is to evaluate the safety, and tolerability of HLA-A*2402 restricted epitope peptide VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in combination with gemcitabine
Condition | Intervention | Phase |
---|---|---|
Pancreatic Cancer |
Biological: VEGFR1-1084, VEGFR2-169 Drug: Gemcitabine |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase I/Ⅱ Sturdy on Antiangiogenic Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer |
Estimated Enrollment: | 15 |
Study Start Date: | September 2007 |
Estimated Study Completion Date: | September 2009 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Phase 1/2 study: Experimental |
Biological: VEGFR1-1084, VEGFR2-169
One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 in group A, on days 3, 10, 17, 24 in group B, or 5, 12, 19, 26 in group C
Drug: Gemcitabine
Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 3, 10 and 17
|
Vascular endothelial growth factor receptor 1 and 2 (VEGFR1 andVEGFR2) are essential targets to tumor angiogenesis, and we identified that peptides derived from these receptors significantly induce the effective tumor specific CTL response in vitro and in vivo. According to these findings, in this trial, we evaluate the safety, tolerability and immune response of these peptide emulsified with Montanide ISA 51 in combination with gemcitabine
Ages Eligible for Study: | 20 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
DISEASE CHARACTERISTICS
PATIENTS CHARACTERISTICS
Laboratory values as follows:
Exclusion Criteria:
Japan | |
Fukushima Medical University Hospital | |
Fukushima, Japan, 960-1295 |
Study Chair: | Mitsukazu Gotoh, M.D. & Ph.D | Fukushima Medical University, Department |
Responsible Party: | Fukushima Medical University ( Department of Surgery I ) |
Study ID Numbers: | FPCR1R2-2 |
Study First Received: | April 4, 2008 |
Last Updated: | February 19, 2009 |
ClinicalTrials.gov Identifier: | NCT00655785 History of Changes |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Epitope peptide CTL Pancreatic cancer Vaccination VEGFR1 VEGFR2 |
Antimetabolites Anti-Infective Agents Digestive System Neoplasms Immunologic Factors Pancreatic Neoplasms Endocrine System Diseases Immunosuppressive Agents Angiogenesis Inhibitors Antiviral Agents |
Recurrence Digestive System Diseases Radiation-Sensitizing Agents Gastrointestinal Neoplasms Pancreatic Diseases Endocrinopathy Gemcitabine Endocrine Gland Neoplasms |
Antimetabolites Anti-Infective Agents Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Pancreatic Neoplasms Physiological Effects of Drugs Neoplasms by Site Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents Gemcitabine |
Endocrine Gland Neoplasms Digestive System Neoplasms Growth Substances Endocrine System Diseases Enzyme Inhibitors Angiogenesis Inhibitors Antiviral Agents Immunosuppressive Agents Pharmacologic Actions Neoplasms Digestive System Diseases Radiation-Sensitizing Agents Pancreatic Diseases |